These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 2203936

  • 1. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
    Schwab M.
    Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
    [Abstract] [Full Text] [Related]

  • 2. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration.
    Schwab M.
    Verh Dtsch Ges Pathol; 1994; 78():26-33. PubMed ID: 7533996
    [Abstract] [Full Text] [Related]

  • 3. Oncogene amplification in neoplastic development and progression of human cancers.
    Schwab M.
    Crit Rev Oncog; 1990; 2(1):35-51. PubMed ID: 2091749
    [Abstract] [Full Text] [Related]

  • 4. MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.
    Schwab M.
    Pathol Oncol Res; 1997; 3(1):3-7. PubMed ID: 11173617
    [Abstract] [Full Text] [Related]

  • 5. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S, Ekstrom L, Lastowska M, Roberts P, Brodeur GM, Kees UR, Schwab M, Bown N.
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [Abstract] [Full Text] [Related]

  • 6. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL, Salwen H, Quasney MW, Ikegaki N, Cowan JM, Herst CV, Kennett RH, Rosen ST, DiGiuseppe JA, Brodeur GM.
    Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
    [Abstract] [Full Text] [Related]

  • 7. Oncogene amplification in solid tumors.
    Schwab M.
    Semin Cancer Biol; 1999 Aug; 9(4):319-25. PubMed ID: 10448118
    [Abstract] [Full Text] [Related]

  • 8. [Oncogene amplification in human neuroblastomas].
    Kanda N, Tsuchida Y, Hayashi Y, Ise T, Takayama J, Utakoji T.
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):661-6. PubMed ID: 3963837
    [Abstract] [Full Text] [Related]

  • 9. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
    Schwab M.
    Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
    [Abstract] [Full Text] [Related]

  • 10. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
    Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G.
    Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
    [Abstract] [Full Text] [Related]

  • 11. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
    Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y, Kuwano M.
    Cancer Res; 1990 May 15; 50(10):3043-7. PubMed ID: 2185879
    [Abstract] [Full Text] [Related]

  • 12. [Tumor cytogenetics and prognosis in neuroblastoma].
    Christiansen H, Lampert F.
    Monatsschr Kinderheilkd; 1989 Oct 15; 137(10):666-71. PubMed ID: 2586532
    [Abstract] [Full Text] [Related]

  • 13. Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification.
    Martinsson T, Ståhl F, Pollwein P, Wenzel A, Levan A, Schwab M, Levan G.
    Oncogene; 1988 Oct 15; 3(4):437-41. PubMed ID: 3078951
    [Abstract] [Full Text] [Related]

  • 14. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells.
    Corvi R, Savelyeva L, Schwab M.
    Cancer Res; 1995 Aug 15; 55(16):3471-4. PubMed ID: 7627947
    [Abstract] [Full Text] [Related]

  • 15. Antiblastic treatment does not affect N-myc gene amplification in neuroblastoma.
    Tonini GP, Verdona G, Garaventa A, Cornaglia-Ferraris P.
    Anticancer Res; 1987 Aug 15; 7(4B):729-32. PubMed ID: 3314672
    [Abstract] [Full Text] [Related]

  • 16. Amplification of cellular oncogenes in cancer cells.
    Alitalo K.
    Med Biol; 1984 Aug 15; 62(6):304-17. PubMed ID: 6398390
    [Abstract] [Full Text] [Related]

  • 17. Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas.
    Schwab M.
    Brain Pathol; 1990 Sep 15; 1(1):41-6. PubMed ID: 1669692
    [Abstract] [Full Text] [Related]

  • 18. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
    Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J, Hale M, Godbout R.
    Oncogene; 1995 Apr 06; 10(7):1417-22. PubMed ID: 7731693
    [Abstract] [Full Text] [Related]

  • 19. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE.
    Clin Cancer Res; 2006 Oct 01; 12(19):5693-7. PubMed ID: 17020972
    [Abstract] [Full Text] [Related]

  • 20. Neuroblastoma: clinical significance of genetic abnormalities.
    Brodeur GM.
    Cancer Surv; 1990 Oct 01; 9(4):673-88. PubMed ID: 2101728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.